Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Why did Trump announce a US-UK trade deal? How are tariffs impacting US manufacturers? What caused Shopify’s profit miss this quarter? Why is Bitcoin nearing $100,000 again? How did Fed rate hold affect markets? Why is Maersk lowering its market outlook? What’s driving layoffs at Match Group? How is AI reshaping CFO roles now? Why did WeightWatchers file for bankruptcy?

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

benzinga.com/general/biotech/25/05/45263171/cencoras-boosts-annual-forecast-on-strong-demand-for-weight-loss-drugs-specialty-products-despite

Cencora, Inc (NYSE:COR) on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.
U.S. Healthcare Solutions revenue was $68.3…

This story appeared on benzinga.com, 2025-05-07 18:06:27.